IRE1α kinase-mediated unconventional protein secretion rescues misfolded CFTR and pendrin.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 32128399.
- Also identified by DOI 10.1126/sciadv.aax9914 and PMC identifier 7030921.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The most prevalent pathogenic mutations in the <i>CFTR</i> (Δ<i>F508</i>) and <i>SLC26A4</i>/pendrin (<i>p.H723R</i>), which cause cystic fibrosis and congenital hearing loss, respectively, evoke protein misfolding and subsequent defects in their cell surface trafficking. Here, we report that activation of the IRE1α kinase pathway can rescue the cell surface expression of ΔF508-CFTR and p.H723R-pendrin through a Golgi-independent unconventional protein secretion (UPS) route. In mammalian cells, inhibition of IRE1α kinase, but not inhibition of IRE1α endonuclease and the downstream effector XBP1, inhibited CFTR UPS. Treatment with the IRE1α kinase activator, (E)-2-(2-chlorostyryl)-3,5,6-trimethyl-pyrazine (CSTMP), rescued cell surface expression and functional activity of ΔF508-CFTR and p.H723R-pendrin. Treatment with a nontoxic dose of CSTMP to ΔF508-CFTR mice restored CFTR surface expression and CFTR-mediated anion transport in the mouse colon. These findings suggest that UPS activation via IRE1α kinase is a strategy to treat diseases caused by defective cell surface trafficking of membrane proteins, including ΔF508-CFTR and p.H723R-pendrin.
Medical subject headings
- Cystic Fibrosis Transmembrane Conductance Regulator
- Endoribonucleases
- Protein Serine-Threonine Kinases
- Signal Transduction
- Sulfate Transporters